AbbVie Inc. Website

AbbVie Inc.

NYSE-ABBV

Company Overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

  • Name

    AbbVie Inc.

  • CEO

    Robert A. Michael

  • Website

    www.abbvie.com

  • Sector

    Biotechnology

  • Year Founded

    2012

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • AbbVie's dividend yield should act as valuation support, as the cash flows to support the dividend look secure over the next several years.

  • AbbVie's strong entrenchment in the aesthetics business (gained through the Allergan acquisition) sets up very long product cycles for several key assets like Botox based on strong brand power and physician entrenchment.

  • AbbVie's next-generation immunology drugs targeting the IL-23 (Skyrizi) and JAK (Rinvoq) pathways are mitigating biosimilar headwinds to older blockbuster Humira.

Bears Say

  • AbbVie has had to depend on acquisitions to boost its late-stage pipeline, suggesting less successful internal research and development activities.

  • AbbVie's Cerevel acquisition saw a setback with the failure of two phase 2 studies for key schizophrenia drug candidate emraclidine.

  • AbbVie's aesthetics business makes the firm more vulnerable to swings in the economy than other biopharma firms, putting pressure on growth when consumer sentiment is low.

Source: Morningstar Analysis - Nov 03, 2025

What's happening

Nov 5, 2025 - Dec 5, 2025

AbbVie Inc. Surges Amid Strategic Growth and Competitive Challenges

  • AbbVie secured FDA approval for EPKINLY, enhancing its portfolio in oncology.
  • The launch of the AbbVie Biotech Innovators Award underscores commitment to biotechnology innovation.
  • Increased competition from generics and Chinese biotechs poses challenges despite strong investor sentiment.

Over the past month, AbbVie Inc. (ABBV) saw a significant increase of 6.7% in its stock price, outperforming the S&P 500's return of 1.3%. This performance reflects strong investor confidence driven by strategic initiatives and product developments within key therapeutic areas such as inflammatory bowel disease (IBD), dermatology, and neuroscience.

Key factors contributing to this positive momentum included recent announcements regarding new product approvals and collaborations aimed at improving operational efficiency. Notably, AbbVie received FDA approval for EPKINLY in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma. Additionally, the company launched the AbbVie Biotech Innovators Award to promote innovation within Quebec's life sciences sector, demonstrating a commitment to supporting early-stage biotechnology companies aligned with its therapeutic focus.

However, some bearish pressures impacted ABBV’s stock performance during this period. Amneal Pharmaceuticals announced FDA approval for a generic equivalent of Restasis, raising concerns about competitive pressures in the ophthalmic market. Furthermore, advancements by Chinese biotechs introduced additional competition that could affect ABBV's position across various therapeutic areas.

Investor interest remained robust due to ongoing research efforts showcased at major conferences like ASH 2025 while social media discussions reflected both optimism regarding potential price movements and caution concerning increased net debt levels linked to recent acquisitions. Analysts maintained generally positive outlooks on ABBV despite mixed signals from quarterly earnings reports that indicated growth in certain segments but also notable revenue declines from Humira due to rising competition.

Overall, throughout this one-month period marked by strategic growth initiatives alongside competitive challenges faced by AbbVie Inc., it outperformed not only the broader S&P 500 index but also surpassed expectations within the Health Care sector (XLV) by an additional margin of 0.5%.

NYSE:ABBV